KCM
ORKA

Kennedy Capital Management’s Oruka Therapeutics ORKA Stock Holding History

Kennedy Capital Management’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.2M Sell
106,863
-19,503
-15% -$1.3M 0.18% 191
2026
Q1 		$6.2M Buy
126,366
+77,680
+160% +$2.7M 0.13% 245
2025
Q4 		$1.48M Buy
48,686
+420
+0.9% +$11.7K 0.03% 449
2025
Q3 		$928K Sell
48,266
-16,660
-26% -$247K 0.02% 508
2025
Q2 		$728K Sell
64,926
-823
-1% -$8.58K 0.02% 530
2025
Q1 		$675K Buy
65,749
+5,255
+9% +$65.5K 0.02% 559
2024
Q4 		$1.17M Buy
+60,494
New +$1.48M 0.03% 580

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Kennedy Capital Management's ORKA Position: Q2 2026 in Review

Kennedy Capital Management reduced its Oruka Therapeutics (ORKA) stake by 15% in Q2 2026, selling an estimated $1.3M and leaving 106,863 shares worth $10.2M. The position accounts for 0.18% of the portfolio, ranked #191.

Kennedy Capital Management first reported a position in ORKA in Q4 2024 and has held it in 7 quarters since. 256 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • Kennedy Capital Management held 106,863 shares of Oruka Therapeutics worth $10.2M as of Q2 2026.
  • Kennedy Capital Management sold 19,503 Oruka Therapeutics shares in Q2 2026, an estimated $1.3M.
  • Oruka Therapeutics made up 0.18% of Kennedy Capital Management's portfolio in Q2 2026, its #191 holding.
  • Kennedy Capital Management first reported a position in Oruka Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 256 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on Kennedy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.